|
|
 |
 |
| |
 Printable version |
Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene? |
Bulletin du Cancer. Volume 86, Number 6, 544-9, Juin 1999, Synthèses
|
 Résumé
Article gratuit
|
Author(s) : Philippe Beuzeboc, Suzy Scholl, Xavier Sastre Garau, Anne Vincent-Salomon, Patricia de Cremoux, Jérôme Couturier, Thao Palangié, Pierre Pouillart |
Summary : HER2 is overexpressed in about 25% to 30% of breast cancers and associated with poor prognosis, resistance to hormonotherapy and lack of sensitivity to CMF-based adjuvant chemotherapy. Herceptin (trastuzumab), a humanized monoclonal antibody, administered as a single agent, produces objective responses in phase II trials in patients with metastatic breast cancers overexpressing HER2. It has shown a substantial benefit in a phase III trial which compares a standard first line chemotherapy (doxorubicin and cyclophosphamid or taxol alone) to the same chemotherapy with Herceptin in metastatic breast cancer. The Herceptin arm had significantly higher response rate (+ 53%), an improvement in the median duration of response (+ 57%) as well as in time to progression (+ 65%) compared to chemotherapy alone. |
Keywords : Herceptin, trastuzumab, c-erbB2, breast cancer. |
|
